The risks of free copper in the body and the development of useful anticopper drugs

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 727-732

  Brewen, George J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b G061X MBNI   (United States)

Author keywords

Alzheimer's disease; Free copper; Tetrathiomolybdate; Wilson's disease

Indexed keywords

ANTICOPPER AGENT; APOLIPOPROTEIN E4; BETA SECRETASE; BLEOMYCIN; BLOCKING AGENT; CERULOPLASMIN; COPPER; COPPER 64; DOXORUBICIN; DRINKING WATER; INTERLEUKIN 1BETA; INTERLEUKIN 2; ISOPROSTANE; METALLOTHIONEIN; MULTIVITAMIN; PARACETAMOL; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA; TRIENTINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CIRCULATION; CLINICAL TRIAL; COGNITIVE DEFECT; COPPER BLOOD LEVEL; COPPER OVERLOAD; DIETARY INTAKE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INHIBITION; DRUG OVERDOSE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FIBROSIS; GASTROINTESTINAL SYMPTOM; HEART INJURY; HUMAN; INFLAMMATION; LEUKOPENIA; LIPID DIET; LIVER; LIVER CIRRHOSIS; LOW DRUG DOSE; MINERAL INTAKE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; RISK ASSESSMENT; TOXICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WILSON DISEASE; ZINC DEFICIENCY;

ALZHEIMER DISEASE; ANGIOGENESIS INHIBITORS; AUTOIMMUNITY; COPPER; FIBROSIS; HEPATOLENTICULAR DEGENERATION; HUMANS; INFLAMMATION; MOLYBDENUM; NEURODEGENERATIVE DISEASES; PENICILLAMINE; TRIETHYLENETETRAMINE;

EID: 55149120720     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328314b678     Document Type: Review

References (51)

1. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Exp Biol Med (Maywood) 2000; 223:39-46.
2. Brewer GJ. Wilson's disease. In: Fauci AS, Braunward E, Kasper DL, et al., editors. Harrison's principles of internal medicine. 17. New York, NY: McGraw-Hill Companies, Inc; 2008. pp. 2449-2452.
3. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956; 21:487-495.
4. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 1992; 71:139-164.
5. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44:490-493.
6. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982; 1:643-647.
7. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63:521-527.
8. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998; 132:264-278.
9. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120:380-386.
10. Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc XVII: treatment during pregnancy. Hepatology 2000; 31:364-370.
11. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 2001; 137:191-198.
12. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60:379-385.
13. Sedlak E, Zoldak G, Wittung-Stafshede P. Role of copper in thermal stability of human ceruloplasmin. Biophys J 2008; 94:1384-1391.
14. Brewer GJ, Ullenbruch MR, Dick RB, et al. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003; 141:210-216.
15. Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004; 98:2160-2167.
16. Flaherty KR, Brewer GJ, Andrei A, et al. A phase I/II trial of tetrathiomolybdate for patients with idiopathic pulmonary fibrosis refractory to previous therapy [abstract]. Am Thorac Soc 2007:A497.
17. Askari FK, Dick RB, Mao M, Brewer GJ. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med (Maywood) 2004; 229:857-863.
18. Song M, Deaciuc IV, Song Z, et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2008; 325:409-416. This is an important study showing protection against fibrosis and inflammation in a key animal model of cirrhosis.
19. Ma S, Hou G, Dick RD, Brewer GJ. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 2004; 4:419-426.
20. Hou G, Dick R, Abrams GD, Brewer GJ. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005; 146:299-303.
21. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the nonobese diabetic mouse model. J Inorg Biochem 2006; 100:927-930.
22. McCubbin MD, Hou G, Abrams GD, et al. Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 2006; 33:2501-2506.
23. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62:4854-4859.
24. Cox C, Merajver SD, Yoo S, et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 2003; 129:781-785.
25. Cox CD, Teknos TN, Barrios M, et al. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001; 111:696-701.
26. Kent MS, Madewell BR, Dank G, et al. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate; a pilot study in a canine animal mode. J Trace Elem Exp Med 2004; 17:9-20.
27. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000; 6:1-10.
28. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003; 9:1666-1672.
29. Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology 2006; 71:168-175.
30. Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 2005; 280:7377-7387.
31. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38:7609-7616.
32. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996; 271:1406-1409.
33. White AR, Multhaup G, Galatis D, et al. Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein. J Neurosci 2002; 22:365-376.
34. Angeletti B, Waldron KJ, Freeman KB, et al. BACE1 cytoplasmic domain interacts with the copper chaperone for Superoxide dismutase-1 and binds copper. J Biol Chem 2005; 280:17930-17937.
35. Ma Q, Li Y, Du J, et al. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006; 27:841-849.
36. Reynolds D. Apolipoprotein E. In: Stanislaus Journal of Biochemical Reviews. Stanislaus, California: California State University; 1997.
37. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55-61.
38. Squittl R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005; 64:1040-1046.
39. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 2003; 100:11065-11069.
40. Deane R, Sagare A, Coma M, et al. A novel role for copper: disruption of LRP-dependent brain Abeta clearance. In: Presentation at the Annual Meeting of the Society for Neuroscience; San Diego, California; 2007. This is important work demonstrating a likely mechanism in which copper and beta amyloid interact to produce toxicity.
41. Fox JH, Kama JA, Lieberman G, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE 2007; 2:e334. This is a good review of the possible toxicity of copper in Huntington's disease.
42. Sigurdsson EM, Brown DR, Alim MA, et al. Copper chelation delays the onset of prion disease. J Biol Chem 2003; 278:46199-46202.
43. Hottinger AF, Fine EG, Gurney ME, et al. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997; 9:1548-1551.
44. Kiaei M, Bush AI, Morrison BM, et al. Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2004; 24:7945-7950.
45. Rasia RM, Bertoncini CW, Marsh D, et al. Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A 2005; 102:4294-4299.
46. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neural 2006; 63:1085-1088. This is an extremely important study that shows that relatively high copper intake, mostly because of supplements, coupled with a high-fat diet, may cause significant cognitive decline in the general population.
47. Hill GM, Brewer GJ, Juni JE, et al. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci 1986; 292:344-349.
48. Hoogenraad TU. Wilson's disease. London: Saunders; 1996.
49. Srikumar TS, Johansson GK, Ockerman PA, et al. Trace element status in healthy subjects switching from a mixed to a lactovegetarian diet for 12 mo. Am J Clin Nutr 1992; 55:885-890.
50. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr 1993; 12:527-530.
51. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, editor. Major problems in internal medicine. Philadelphia: W.B. Saunders Company; 1984 pp. 1-171.